IngredientesBeta-lapachone (β-lap), formally designated 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione, is an ortho-naphthoquinone natural product isolated from the lapacho tree (Tabebuia avellanedae) in many regions of South America. It is assigned CAS registry number 4707-32-8. Beta-lapachone is an ortho-naphthoquinone originally isolated from the heartwood of Handroanthus impetiginosus and can be obtained through synthesis from lapachol, naphthoquinones, and other aromatic compounds. The compound belongs to the broader naphthoquinone chemical class, a group of highly reactive organic species characterized by their prooxidant nature and broad interaction with biological systems.
Beta-lapachone is an ortho-naphthoquinone that presents an orange crystalline form and a melting point of 154–156 °C. It has low solubility in water and is thermally stable up to 191 °C, reporting two enthalpy events: the first endothermic and the second exothermic, corresponding to the melting process and decomposition, respectively. As a naphthoquinone, beta-lapachone is a hydrophobic compound with low solubility in aqueous medium and, consequently, low bioavailability, which limits the progress of studies regarding its pharmacological applications.
Beta-lapachone is an ortho-naphthoquinone natural product isolated from the lapacho tree (Tabebuia avellanedae) in many regions of South America. The taxonomy of this tree has undergone revision: Tabebuia avellanedae is now more frequently recognized under the synonymous scientific name Handroanthus impetiginosus, belonging to the family Bignoniaceae. Beta-lapachone is a bioactive natural molecule derived from plants like Austroplenckia populnea and Tabebuia avellanedae.
Beta-lapachone is a natural substance that is easily obtained from lapachol, which is found as a minor constituent of the heartwood of trees of the family Bignoniaceae, known in Brazil as Ipê. Major constituents of T. impetiginosa are furanonaphthoquinones, naphthoquinones, anthraquinones, quinones, benzoic acid, flavonoids, cyclopentene dialdehydes, coumarins, iridoids, and phenolic glycosides. The presence of naphthoquinones attracted scientific attention, with lapachol and beta-lapachone especially piquing the interest of professionals in the medical field.
Lapachol, beta-lapachone, and alpha-lapachone are three well-studied natural products isolated from Tabebuia impetiginosa, having most interesting chemodiversity and demonstrating diverse biological effects. While beta-lapachone occurs naturally in the tree, it is more typically produced semi-synthetically via acid-catalyzed cyclization of lapachol — the more abundant naphthoquinone found in the bark — for research and pharmaceutical purposes.
As a pure compound, beta-lapachone is encountered primarily in research and investigational pharmaceutical contexts rather than as a standalone commercial dietary supplement. The bark of source trees is sold in health food stores under various names such as "pau d'arco" or "lapacho." Traditional preparations derive from the broader plant, not isolated beta-lapachone.
In pharmaceutical and experimental settings, beta-lapachone's poor aqueous solubility has driven extensive formulation research. Cyclodextrins have been explored to form inclusion complexes with beta-lapachone to overcome solubility and bioavailability problems, with complexes between beta-lapachone and four cyclodextrins (α-, β-, γ-, and HPβ-CD) investigated by phase solubility studies, fluorescence, and 1H-NMR spectroscopy. Maximum solubility of beta-lapachone was achieved at 16.0 mg/ml or 66.0 mM with HPβ-CD, and fluorescence and 1H-NMR spectroscopy proved the formation of 1:1 inclusion complexes between β-CD and HPβ-CD with beta-lapachone. Clinical investigational formulations have included ARQ 501 and ARQ 761, both hydroxypropyl-beta-cyclodextrin (HPβCD) complexes used in intravenous administration.
Species of the genus Tabebuia have been used historically in the Amazonian region for the treatment of several diseases, including syphilis, fevers, malaria, cutaneous infections, and stomach disorders. Traditionally, the botanical drug is widely used in local and traditional phytomedicine, usually ingested as a decoction prepared from the inner bark of the tree to treat numerous conditions like bacterial and fungal infections, fever, syphilis, malaria, trypanosomiasis, as well as stomach and bladder disorders.
The preparation most commonly used across cultures in South America is a hot water decoction (tea) of the inner bark — known as pau d'arco, lapacho, or taheebo — rather than any isolated constituent. Beta-lapachone, along with lapachol, is one of the main bioactive compounds present in such preparations, though the concentration of isolated beta-lapachone in traditional aqueous bark teas is relatively low.
As early as 1873, biomedical uses of Red Lapacho ("Pau D'Arco") were reported. In 1967, after reports in the Brazilian press, it came back to the light of clinicians and the public in general. The news magazine O'Cruzeiro started reporting "miraculous" cures in cancer patients in a hospital. Starting in the 1960s, claims for clinical efficacy in the treatment of cancers, particularly in Brazil, resulted in widespread sales of the stem bark and trunk wood of Tabebuia impetiginosa.
Natural sciences interest in the plant also began in the 1960s when the United States National Cancer Institute (NCI) systematically began researching plant extracts all over the world looking for active compounds against cancer and looked at Tabebuia impetiginosa in considerable detail. Between 1960 and 1990, the US National Cancer Institute (NCI) conducted research on the use of natural products, including lapachol and beta-lapachone, for the treatment of cancer. Studies using lapachol were discontinued due to toxicity, but research evaluating the anticancer activity of beta-lapachone continued.
In South America there is a long tradition of local and traditional use, and the drug is now often acclaimed to be a wonder drug for curing most notably cancer. In 1999, the US Food and Drug Administration (FDA) listed red lapacho tea as a dietary supplement and an "herb used to alleviate conditions and symptoms of cancer."
The inner bark and heartwood of red lapacho contains several natural compounds, such as benzoic acid and benzaldehyde derivatives, cyclopentene dialdehydes, flavonoids, furanonaphthoquinones, quinones, naphthoquinones, and anthraquinones. Lapachol (2-hydroxy-3-(3-methylbut-2-en-1-yl)naphthalene-1,4-dione, C15H14O3), which has anticancer properties, was the first naphthoquinone isolated from the heartwood of red lapacho.
Two main bioactive components have been isolated from Tabebuia impetiginosa: lapachol and beta-lapachone. Of the many bioactive compounds isolated, the naphthoquinones, particularly lapachol and beta-lapachone, have received most attention. Beta-lapachone can also be produced semi-synthetically from lapachol by acid-catalyzed cyclization, making it accessible at quantities beyond what is obtained purely through plant extraction.
Beta-lapachone is bioactivated by NAD(P)H:quinone oxidoreductase 1 (NQO1). This enzyme exhibits elevated expression in most solid cancers and therefore is a potential cancer-specific target. NQO1 is a two-electron oxidoreductase expressed in cancer tissue at levels 5- to 200-fold greater than in normal tissue.
Beta-lapachone's therapeutic efficacy partially stems from the drug's induction of a futile NQO1-mediated redox cycle that causes high levels of superoxide and then peroxide formation, which damages DNA and causes hyperactivation of poly(ADP-ribose) polymerase, resulting in extensive NAD+/ATP depletion. More precisely, this process involves the reduction of beta-lapachone to an unstable hydroquinone form, which can spontaneously react with two oxygen molecules in a two-step reverse reaction to regenerate the original form of beta-lapachone, thereby mediating a futile redox cycle, and a large amount of reactive oxygen species (ROS) rapidly accumulates during this process, triggering a cascade of downstream reactions that ultimately result in cell death.
Elevated, cell membrane-permeable hydrogen peroxide pools lead to extensive oxidative DNA lesions, particularly base and DNA single strand breaks, that "hyperactivate" poly(ADP-ribosyl) polymerase 1 (PARP1). The net result is that elevated levels of NAD+ created by NQO1 futile redox cycling of beta-lapachone are subsequently degraded by hyperactivated levels of PARP1, and rapid and dramatic depletion of intracellular NAD+ pools occur within 20–30 minutes of beta-lapachone exposure in NQO1+ cancer cells.
NQO1+ cancer cells exposed to beta-lapachone uniformly die in an NQO1-dependent manner and in an oncogene driver- or passenger-independent manner, dying independently of p53, BAX, BCL2, or other tumor suppressor losses. This independence from classic tumor suppressor pathways is considered a key advantage.
Kinetically, beta-lapachone-induced cell death is characterized by: (i) dramatic reactive oxygen species (ROS) formation, eliciting extensive DNA damage; (ii) hyperactivation of poly(ADP-ribose)polymerase-1 (PARP-1); (iii) depletion of NAD+/ATP levels; and (iv) proteolytic cleavage of p53/PARP-1, indicating μ-calpain activation and apoptosis. Cancer cells die through an ROS-induced, μ-calpain-mediated programmed cell death process that kills independent of caspase activation and is not driven by PAR accumulation, which researchers term "NAD+-Keresis."
Beta-lapachone is well known to inhibit topoisomerase I and to induce NAD(P)H:quinone oxidoreductase 1. It acts as a novel DNA topoisomerase I inhibitor which, unlike camptothecin, does not stabilize the cleavable complex, indicating a novel mode of action. This mechanism is distinct from the NQO1 redox cycling pathway and may contribute to cytotoxic effects in cells with lower NQO1 expression.
Beta-lapachone is a derivative of the naturally occurring element lapachol, from Tabebuia avellanedae, and its anti-inflammatory effects have been reported in several studies. Cell and animal studies support the anti-inflammatory role of beta-lapachone and have identified potential mechanisms. Mechanism studies on derivatives indicate anti-inflammatory properties involve suppressing the release of pro-inflammatory factors through down-regulating NF-κB activation, and suppression of NF-κB translocation by inhibiting the phosphorylation of p38 kinase.
Beta-lapachone suppresses inflammatory responses in activated macrophages and protects from lung edema and high mortality in septic mice.
NQO1 modulates the cellular NAD+/NADH ratio, which has been associated with the aging and anti-aging mechanisms of calorie restriction. In cancer contexts, beta-lapachone causes dramatic NAD+ depletion; however, in non-cancerous settings and at lower doses, beta-lapachone's modulation of NQO1 activity can upregulate cellular NAD+ levels. Beta-lapachone's activity at NQO1 has been shown to modulate NAD+/NADH metabolism, resulting in the prevention of cognitive and motor deterioration, protection against nephrotoxicity induced by acute kidney injury, reduction in inflammation through the immunomodulation of arthritis, and promotion of wound healing.
Beta-lapachone is a potent cytotoxic agent that demonstrates antitumor activity against a variety of human cancer cells at concentrations typically in the range of 1–10 μM (IC50). Cytotoxicity has been demonstrated in transformed cell lines derived from patients with promyelocytic leukemia, prostate, malignant glioma, hepatoma, colon, breast, ovarian, pancreatic, and multiple myeloma cell lines, including drug-resistant lines.
Beta-lapachone has been tested for toxicity against over 300 NQO1+ non-small cell lung, pancreatic, breast, prostate, and head and neck cancer cell lines, showing the same 30–60-minute minimum time of exposure for NQO1-dependent and NAD+/ATP-mediated programmed necrosis.
This ortho-naphthoquinone has been widely studied, mainly by presenting selective effects on tumor cell lines compared to normal strains. This natural compound has shown activity against several types of malignant tumors, such as lung and pancreatic cancers and melanoma. The selectivity appears rooted in the differential expression of NQO1: ARQ761 undergoes a robust, futile redox cycle in NQO1+ cancer cells, producing massive hydrogen peroxide (H2O2) levels; normal tissues are spared by low NQO1 and high catalase expression.
A 2024 study using mouse models demonstrated that beta-lapachone, as an NQO1 bioactivatable drug, was used to suppress lung tumorigenesis, and the efficacy and safety of low-dose beta-lapachone were demonstrated in preventing lung tumorigenesis in vivo, with the study concluding that long-term consumption of low-dose beta-lapachone could potentially be an effective therapeutic strategy for the prevention of lung premalignant lesions.
Multiple Phase I and Phase II clinical trials of beta-lapachone and its derivatives (clinical form: ARQ 501, ARQ 761, and MB12066) have been conducted for the treatment of cancer and metabolic syndrome.
The most detailed published clinical data come from a Phase 1 study of ARQ 761. A 3+3 dose escalation study of three schedules (weekly, every other week, 2/3 weeks) of ARQ 761 was performed in patients with refractory advanced solid tumours, with tumour tissue analysed for NQO1 expression, and after 20 patients were analysed, enrolment was restricted to patients with NQO1-high tumours (H-score ≥ 200). A total of 42 patients were treated, with a median number of prior lines of therapy of 4. Maximum tolerated dose was 390 mg/m² as a 2-hour infusion every other week, and dose-limiting toxicity was anaemia. Among 32 evaluable patients, best response was stable disease (n = 12); 6 patients had tumour shrinkage. There was a trend towards improved efficacy in NQO1-high tumours (P = 0.06). ARQ 761 showed modest single-agent activity, which appears associated with tumour NQO1 expression.
In the first in human Phase 1 clinical trial of monotherapy ARQ 761, NQO1 expression was found to be a principal determinant of disease response. Beta-lapachone has attracted great attention for its anticancer activity, and it has already been tested in Phase II clinical trials for the treatment of pancreatic cancer.
Beta-lapachone has two main shortcomings: insolubility in water and systemic dose-limiting toxicity. It advanced to clinical trials for pancreatic ductal adenocarcinoma (PDAC) in two solubilizing formulations, ARQ 501 (Phase II) and ARQ 761 (Phase I/Ib), which both showed moderate efficacy by stabilizing disease in patients.
Evidence strength assessment: For oncology applications, the available human clinical data are preliminary and limited to Phase 1/2 investigational trials with small patient numbers. No completed randomized controlled trials have been published establishing efficacy in any cancer type. The mechanistic preclinical evidence base is robust, but clinical translation has been constrained by toxicity. Evidence remains insufficient to support clinical conclusions about efficacy.
The treatment of Chagas disease, a neglected parasitic condition caused by Trypanosoma cruzi, is still based on only two drugs with limited efficacy in the late chronic phase and severe side effects. In this context, the natural naphthoquinone beta-lapachone and its derivatives have demonstrated important trypanocidal activities. Unfortunately, the decrease in trypanocidal activity in the blood, high toxicity to mammalian cells, and low water solubility of beta-lapachone limit its systemic administration and, consequently, clinical applications.
Lapachol and beta-lapachone derived from Tabebuia avellanedae promoted striking cell morphological alterations, mitochondrial depolarization, DNA fragmentation, decrease of the infection index in the amastigotes assay, and decrease of cytokines against Leishmania amazonensis in preclinical studies.
Evidence strength assessment: Antiparasitic evidence for beta-lapachone is limited to in vitro and animal studies. No human clinical trials of isolated beta-lapachone for trypanosomiasis or leishmaniasis have been published. Evidence is preliminary.
Researchers investigated whether beta-lapachone has anti-inflammatory effects under in vitro and in vivo neuroinflammatory conditions, examining the effects on the expression of inducible nitric oxide synthase (iNOS), cytokines, and matrix metalloproteinases (MMPs) in LPS-stimulated BV2 microglial cells and rat primary microglia. In this cell and animal study, beta-lapachone demonstrated suppression of neuroinflammatory markers.
Anti-inflammatory activities of beta-lapachone may be due to synergistic mechanisms. Studies to date examining anti-inflammatory activity have been conducted in cell cultures and animal models only. No human clinical trials have been conducted or published for inflammatory conditions as a primary endpoint.
Evidence strength assessment: Anti-inflammatory evidence is entirely preclinical (in vitro and animal). No human data exist.
Beta-lapachone has shown beneficial antimicrobial effects against Toxocara canis larvae, Coccidioides posadasii, Cryptococcus neoformans, Staphylococcus hemolyticus, methicillin-resistant Staphylococcus aureus, rifampicin-resistant Mycobacterium tuberculosis, and fluconazole-resistant Candida albicans. Lapachol is an important compound of the naphthoquinones class, which has been related to antiviral, antiparasitic, antimicrobial, anti-inflammatory, analgesic, anticancer, anti-metastatic, fungicide, and antioxidant activities. These activities have been demonstrated in laboratory (in vitro) models.
Evidence strength assessment: Antimicrobial evidence is in vitro only. No human clinical data support use for infection.
NQO1 modulates the cellular NAD+/NADH ratio, which has been associated with aging and anti-aging mechanisms of calorie restriction. Facilitation of NQO1 activity by feeding beta-lapachone, as an exogenous NQO1 co-substrate, prevented age-dependent decline of motor and cognitive function in aged mice. Beta-lapachone-fed mice did not alter their food-intake or locomotor activity but did increase their energy expenditure as measured by oxygen consumption and heat generation. Mitochondrial structure and numbers were disorganized and decreased in the muscles of the control diet group, but those defects were less severe in beta-lapachone-fed aged mice. Furthermore, for a subset of genes associated with energy metabolism, mice fed the beta-lapachone diet showed similar changes in gene expression to the calorie restriction group.
Evidence strength assessment: Neurological and aging-related effects have been demonstrated only in animal models. There are no human clinical trial data for these endpoints.
A low dose of beta-lapachone was shown to enhance proliferation in several cell types, facilitate the migration of mouse 3T3 fibroblasts and human endothelial EAhy926 cells through different MAPK signaling pathways, and accelerate scrape-wound healing in vitro. Application of ointment with or without beta-lapachone to a punched wound in normal and diabetic (db/db) mice showed that the healing process was faster in beta-lapachone-treated animals than in those treated with vehicle only. Beta-lapachone also induced macrophages to release VEGF and EGF, which are beneficial for growth of many cells. The results showed that beta-lapachone can increase cell proliferation, including keratinocytes, fibroblasts, and endothelial cells, and migration of fibroblasts and endothelial cells, and thus accelerate wound healing.
Evidence strength assessment: Wound-healing evidence is from in vitro and animal studies only. No human clinical trials have been conducted.
Beta-lapachone itself has not been standardized in any pharmacopeia or official monograph as an isolated compound for human dietary supplementation. Its appearance in clinical trials has been exclusively in investigational pharmaceutical formulations. It advanced to clinical trials for PDAC in two solubilizing formulations, ARQ 501 (Phase II) and ARQ 761 (Phase I/Ib), which both showed moderate efficacy by stabilizing disease in patients.
A 302-fold increase of solubility was achieved for beta-lapachone in HPβ-CD solution, with a constant of association K1:1 of 961 M⁻¹ and a complexation efficiency of 0.1538. These inclusion complexes form the basis of the clinical formulations.
In the Phase 1 clinical trial of ARQ 761 (a beta-lapachone analogue): the maximum tolerated dose was 390 mg/m² as a 2-hour infusion every other week, and dose-limiting toxicity was anaemia. Single-agent clinical activity was seen starting at the first dose level studied (195 mg/m²).
In preclinical cancer research, beta-lapachone demonstrates antitumor activity against a variety of human cancer cells at concentrations typically in the range of 1–10 μM (IC50).
In the mouse aging study, beta-lapachone was administered as a dietary supplement in feed, with effects on NAD+/NADH metabolism, motor function, and mitochondrial integrity observed; exact dietary concentration dosages for this model were described in the original study (Lee et al., 2012, PLoS One).
Traditional use involves decoctions of the inner bark of Tabebuia species, consumed as a tea. No standardized dosage of beta-lapachone content has been established for these preparations, and the concentration of isolated beta-lapachone in aqueous bark extracts is variable and generally low. Beta-lapachone as a pure isolated supplement is not a standard commercial product with an established dosing protocol supported by human studies.
In clinical trials, various adverse effects of ARQ 761 were observed in patients, including anaemia (79%), fatigue (45%), hypoxia (33%), and methemoglobinemia (26%). Major dose-limiting side effects of anaemia and methemoglobinaemia were observed due to off-target redox cycling of the ortho-quinone pharmacophore by interaction with the b5 reductase 1 (CYB5R1) enzyme expressed ubiquitously in mammalian erythrocyte cells.
The major toxicities of ARQ761 monotherapy have been methemoglobinaemia and haemolytic anaemia. Other toxicities normally associated with conventional cytotoxic regimens such as nausea, neutropenia, and thrombocytopenia were not observed.
A major limitation of current formulations of beta-lapachone in Phase I clinical trials (i.e., ARQ761) is methemoglobinaemia, limiting the antitumor efficacy of this otherwise NQO1-targeted antitumor agent. Further clinical translation has been significantly hindered by toxicity issues including haemolytic anaemia, methemoglobinaemia, and other side effects discovered in clinical trials.
The therapeutic and toxic profile of beta-lapachone is strongly modulated by NQO1 enzyme status. Some cancer cell lines contain a homozygous *2 NQO1 polymorphism and lack NQO1 expression. Genetically matched NQO1+ cells were previously generated to test NQO1-specific lethality responses to beta-lapachone. Individuals who carry the NQO1 *2 polymorphism (NQO1-null phenotype) would be expected to have substantially diminished cellular response to beta-lapachone's primary redox mechanism. Conversely, high NQO1 expression increases sensitivity to beta-lapachone's cytotoxic and potentially toxic effects.
Beta-lapachone is a hydrophobic compound with low solubility in aqueous medium and, consequently, low bioavailability, limiting the progress of studies regarding its pharmacological applications, and it has systemic toxicity and unequal distribution in parenteral administration.
The drug appears to be generally safe, and one of the most important interactions of Tabebuia impetiginosa has been associated with interference in the biological cycle of Vitamin K in the body. This interaction has been attributed principally to lapachol, the most abundant naphthoquinone constituent, rather than specifically to beta-lapachone at concentrations present in traditional bark tea preparations.
Pau d'arco tea can reportedly cause nausea and vomiting. Haemolytic anaemia has been reported as a limiting toxicity in animals. When administered to patients with cancer, beta-lapachone did not exhibit dose-limiting toxicity. Adverse events were mild and included anaemia, haemolysis, hyperbilirubinaemia, oedema, nausea, constipation, and fatigue.
Exposure to wood and/or wood dust from Tabebuia species can lead to asthma and fixed eruption (erythematous, pruritic, hyperpigmented skin eruptions).
Related mechanisms of beta-lapachone have been widely investigated for a full understanding of its therapeutic potentials. Numerous derivatives of beta-lapachone have been reported with aims to generate new chemical entities, improve the corresponding biological potency, and overcome disadvantages of its physical and chemical properties and safety profiles.
NQO1 expression is being developed as a companion diagnostic with ARQ761 and is used as an integral biomarker on clinical trials. This represents a move toward precision oncology approaches in which NQO1 tumour expression would guide patient selection. Identifying novel approaches to enhance the therapeutic effects of beta-lapachone without the need for dose escalation could provide a promising strategy against cancer types that exhibit high NQO1 levels, and several drug delivery systems and reformulations have been developed to enhance its bioavailability.
The compound's role as a natural product in dietary supplement form remains scientifically underdeveloped. Most human exposure to beta-lapachone in a supplement context occurs indirectly through traditional bark preparations (pau d'arco tea), and the concentration of beta-lapachone as an isolated entity in such preparations has not been standardized. All evidence for specific, isolated beta-lapachone effects in humans derives from investigational pharmaceutical clinical trials, not from dietary supplement use.
Condiciones de salud que beta-lapachona puede ayudar a apoyar.
Beta-lapachone is a naphthoquinone compound from pau d'arco bark that demonstrated 84% inhibition of Candida biofilm formation in a 2018 in vitro study and blocked the yeast-to-hyphae transition. It shows activity against fluconazole-resistant Candida strains, making it particularly relevant for resistant-strain Candida cleanse protocols.
Sistemas corporales que beta-lapachona puede ayudar a apoyar.
Volver